Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Roden

Showing results (81-90 of 684) with videos related to

Pageof 69
Sort By:
Nature Reviews. Endocrinology|October 16, 2023
Inter-organ crosstalk during development and progression of type 2 diabetes mellitusGeorgia Xourafa, Melis Korbmacher, Michael Roden
The New England Journal of Medicine|May 23, 2003
Ghrelin concentrations in morbidly obese patients after adjustable gastric bandingUrsula Hanusch-Enserer, Georg Brabant, Michael Roden
Nature Reviews. Gastroenterology & Hepatology|October 13, 2016
NAFLD and diabetes mellitusHerbert Tilg, Alexander R Moschen, Michael Roden
Diabetes/Metabolism Research and Reviews|September 1, 2025
Metabolic Cardiovascular Renal Disease (Met-CVRD): A New NomenclaturePaolo Pozzilli, Maria Vittoria Messina, Michael Roden
Metabolism: Clinical and Experimental|June 23, 2020
Metabolic liver disease in diabetes - From mechanisms to clinical trialsBedair Dewidar, Sabine Kahl, Kalliopi Pafili, et al.
Diabetologia|March 25, 2023
Diabetes and climate change: current evidence and implications for people with diabetes, clinicians and policy stakeholdersJacqueline M Ratter-Rieck, Michael Roden, Christian Herder
Acta Diabetologica|December 12, 2024
The potential of precision diabetology for type 2 diabetes treatment-evidence from a meta-regression for all-cause mortality from large cardiovascular outcome trialsOliver Kuss, Michael Roden, Sabrina Schlesinger, et al.
Deutsche Medizinische Wochenschrift (1946)|November 14, 2013
[Rare cause for severe hypertriglyceridemia - case 9/2013]Sabine Kahl, Michael Roden, Klaus Mörike, et al.
Wiener Klinische Wochenschrift|January 7, 2006
Insulin glargine in combination with oral antidiabetic drugs as a cost-equivalent alternative to conventional insulin therapy in type 2 diabetes mellitusMonika Lechleitner, Michael Roden, Eva Haehling, et al.
Deutsche Medizinische Wochenschrift (1946)|February 1, 2019
[The Diabetic Heart and Heart Failure - Update on Mechanisms and Therapy]Elric Zweck, Julia Szendrödi, Malte Kelm, et al.
Pageof 69

Showing results (81-90 of 684) with videos related to

Sort By:
Pageof 69
Nature Reviews. Endocrinology|October 16, 2023
Inter-organ crosstalk during development and progression of type 2 diabetes mellitusGeorgia Xourafa, Melis Korbmacher, Michael Roden
The New England Journal of Medicine|May 23, 2003
Ghrelin concentrations in morbidly obese patients after adjustable gastric bandingUrsula Hanusch-Enserer, Georg Brabant, Michael Roden
Nature Reviews. Gastroenterology & Hepatology|October 13, 2016
NAFLD and diabetes mellitusHerbert Tilg, Alexander R Moschen, Michael Roden
Diabetes/Metabolism Research and Reviews|September 1, 2025
Metabolic Cardiovascular Renal Disease (Met-CVRD): A New NomenclaturePaolo Pozzilli, Maria Vittoria Messina, Michael Roden
Metabolism: Clinical and Experimental|June 23, 2020
Metabolic liver disease in diabetes - From mechanisms to clinical trialsBedair Dewidar, Sabine Kahl, Kalliopi Pafili, et al.
Diabetologia|March 25, 2023
Diabetes and climate change: current evidence and implications for people with diabetes, clinicians and policy stakeholdersJacqueline M Ratter-Rieck, Michael Roden, Christian Herder
Acta Diabetologica|December 12, 2024
The potential of precision diabetology for type 2 diabetes treatment-evidence from a meta-regression for all-cause mortality from large cardiovascular outcome trialsOliver Kuss, Michael Roden, Sabrina Schlesinger, et al.
Deutsche Medizinische Wochenschrift (1946)|November 14, 2013
[Rare cause for severe hypertriglyceridemia - case 9/2013]Sabine Kahl, Michael Roden, Klaus Mörike, et al.
Wiener Klinische Wochenschrift|January 7, 2006
Insulin glargine in combination with oral antidiabetic drugs as a cost-equivalent alternative to conventional insulin therapy in type 2 diabetes mellitusMonika Lechleitner, Michael Roden, Eva Haehling, et al.
Deutsche Medizinische Wochenschrift (1946)|February 1, 2019
[The Diabetic Heart and Heart Failure - Update on Mechanisms and Therapy]Elric Zweck, Julia Szendrödi, Malte Kelm, et al.
Pageof 69